News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Opko Health, Inc. Completes Acquisition of NK-1 Compounds from Schering Corporation
November 11, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE Amex:OPK) today announced that it has completed the acquisition of rolapitant and a related compound from Schering Corporation, a subsidiary of Merck & Co., Inc. ("Schering").
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
MORE ON THIS TOPIC
Cardiovascular disease
Alnylam Unites With Tenaya in Potential $1B+ Pact To Find New Genetic Heart Disease Targets
March 5, 2026
·
2 min read
·
Heather McKenzie
Funding
Teva Bags $400M Backing From Blackstone To Advance Sanofi-Partnered Drug
March 4, 2026
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Sanofi Bets Up to $1.53B in Hong Kong Immuno Pact, Adding to String of Deals
March 4, 2026
·
2 min read
·
Tristan Manalac
Deals
Boehringer Seeks To Rebalance Immunity With Sitryx Collab Potentially Worth $500M+
February 26, 2026
·
1 min read
·
Tristan Manalac
